Entrar/Registro  
INICIO ENGLISH
 
Revista Mexicana de Neurociencia
   
MENÚ

Contenido por año, Vol. y Num.

Índice de este artículo

Información General

Instrucciones para Autores

Mensajes al Editor

Directorio






>Revistas >Revista Mexicana de Neurociencia >Año 2005, No. 5


Ortega-Martínez MG, Jaramillo-Rangel G, Ancer-Rodríguez J, Trujillo JR
Mimetismo molecular en la neuropatogénesis del síndrome de Guillain-Barré
Rev Mex Neuroci 2005; 6 (5)

Idioma: Español
Referencias bibliográficas: 60
Paginas: 440-447
Archivo PDF: 91.66 Kb.


Texto completo




RESUMEN

El síndrome de Guillain-Barré (SGB) es la neuropatía autoinmune más común. Clínicamente se caracteriza por parálisis flácida, aguda y ascendente, que generalmente es precedida por una infección viral o bacteriana. El Campylobacter jejuni y el citomegalovirus (CMV) son los agentes patógenos encontrados con más frecuencia en las infecciones que anteceden a esta enfermedad. La infección por el virus de la inmunodeficiencia (VIH) puede complicarse con un SGB, que usualmente ocurre antes del desarrollo del SIDA. El SGB asociado al VIH se ha convertido en un gran problema, y no está muy claro si se relaciona con la misma infección por el VIH o a la reactivación de otros virus como el CMV. El mimetismo molecular entre componentes microbianos y del hospedero es el mecanismo responsable de la respuesta inmune humoral y celular involucrada en la neuropatogénesis del SGB y de otras enfermedades autoinmunes postinfecciosas. En esta revisión analizamos el papel del mimetismo molecular como el mecanismo causal del SGB.


Palabras clave: Síndrome de Guillain-Barré, neuropatogénesis, mimetismo molecular.


REFERENCIAS

  1. Ang CW, Jacobs BC, Laman JD. The Guillain-Barré syndrome: a true case of molecular mimicry. Trends Immunol 2004; 25(2): 61-6.

  2. Puga-Torres S, Padrón-Sánchez A, Bravo-Pérez R. Síndrome de Guillain Barré. Rev Cubana Med Milit 2003; 32(2): 137-42.

  3. Anthony DC, Frosch MP, De Girolami U. Guillain-Barré syndrome (acute inflammatory demyelinating polyradiculoneuropathy). Kumar V, Abbas AK, Fausto N, eds. Robbins and Cotran Pathologic Basis of Disease, 7th ed. Saunders Elsevier Science; 2005. p. 1331.

  4. Shields RW Jr., Wilbourn AJ. Demyelinating disorders of the peripheral nervous system. Goetz CG, ed. Goetz: Textbook of Clinical Neurology, 2nd ed. Saunders Elsevier Science; 2003, p. 1083-90.

  5. Griffin JW. Peripheral neuropathies. Arend WP, Armitage JO, Drazen JM, Gill GN, Griggs RC, Powell DW, Scheld WM, eds. Goldman: Cecil Textbook of Medicine, 22nd ed. W.B. Saunders Company; 2004, p. 2379-80.

  6. Hahn AF. Guillain Barré syndrome. Lancet 1998; 352(9128): 635-41.

  7. Ávila-Funes JA, Mariona-Montero VA, Melano-Carranza E. Síndrome de Guillain-Barré: Etiología y patogénesis. Rev Invest Clin 2002; 54(4): 357-63.

  8. Kiefer R, Kieseir BC, Stoll G, Hartung HP. The role of macrophages in immune-mediated damage to the peripheral nervous system. Prog Neurobiol 2001; 64(2): 109-27.

  9. Press R, Ozenci V, Kouwenhoven M, Link H. Non-TH1 cytokines are augmented systematically early in Guillain-Barré syndrome. Neurology 2002; 58(3): 476-8.

  10. Créange A, Bélec L, Clair B, Degos JD, Rapha¸l JC, Gherardi RK. Circulating transforming growth factor beta 1 (TGFb1) in Guillain-Barré syndrome: decreased concentrations in the early course and increase with motor function. J Neurol Neurosurg Psychiatry 1998; 64(2): 162-5.

  11. Kieseier BC, Kiefer R, Gold R, Hemmer B, Willison HJ, Hartung HP. Advances in understanding and treatment of immune-mediated disorders of the peripheral nervous system. Muscle Nerve 2004; 30(2): 131-56.

  12. Albert LJ, Inman RD. Molecular mimicry and autoimmunity. N Engl J Med 1999; 341(27): 2068-74.

  13. Croxford JL, Olson JK, Anger HA, Miller SD. Initiation and exacerbation of autoimmune demyelination of the central nervous system via virus-induced molecular mimicry: implications for the pathogenesis of multiple sclerosis. J Virol 2005; 79(13): 8581-90.

  14. Trujillo JR, Ramírez-Rodríguez C. Mimetismo molecular en el síndrome del complejo demencial del SIDA. Rev Mex Neuroci 2000; 1(3): 8-11.

  15. Trujillo JR, Navia B, Benowitz L, MacLane MF, Worth J, Lee TH, Essex M. Evaluation of autoantibodies to human brain proteins in patients with AIDS dementia complex. J Acquir Immune Defic Syndr 1994; 7(2): 103-8.

  16. Trujillo JR, Navia BA, McLane MF, Worth J, Lucey DR, Lee TH, Essex M. Higher levels of anti-HIV-1 envelope antibodies in cerebrospinal fluid of patients with AIDS dementia complex. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 12(1): 19-25.

  17. Trujillo JR, McLane MF, Lee TH, Essex M. Molecular mimicry between human immunodeficiency virus type 1 gp120 V3 loop and human brain proteins. J Virol 1993; 67(12): 7711-15.

  18. Trujillo JR, McLane MF, de la Monte S, Navia B, Brain JD, Essex M. Molecular mimicry in HIV-1 neuropathogenesis: human antibodies that bind to gp120 V3 loop and human brain proteins. J Neurovirol 1996; 2: 21.

  19. Trujillo JR, Rogers RA, Brain JD. Share antigenic epitopes on the V3 loop of HIV-1 gp120 and proteins on activated human T-cells. Virology 1998; 246(1): 53-62.

  20. Trujillo JR, McLane MF, Essex M. Molecular mimicry between the V3 loop of HIV-1 gp120 and the neuronal protooncogene N-Myc. Neurology 1994; 44(Suppl 2): S396.

  21. Trujillo JR, Essex M, Brain JD. HIV-1 Molecular mimicry and neuronal apoptosis. J Neurovirol 2000; 6: 257.

  22. Jacobs BC, Rothbarth PH, van der Meché FG, Herbrink P, Schmitz PI, de Klerk MA, van Doorn PA. The spectrum of antecedent infections in Guillain-Barré syndrome: a case-control study. Neurology 1998; 51(4): 1110-15.

  23. Willison HJ, Yuki N. Peripheral neuropathies and anti-glycolipid antibodies. Brain 2002; 125(12): 2591-2625.

  24. Hughes RA, Hadden RD, Gregson NA, Smith KJ. Pathogenesis of Guillain-Barré syndrome. J. Neuroimmunol 1999; 100(1-2): 74-97.

  25. Ben-Smith A, Gaston JS, Barber PC, Winer JB. Isolation and characterization of T lymphocytes from sural nerve biopsies in patients with Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry 1996; 61(4): 362-8.

  26. Ang CW, Laman JD, Willison HJ, Wagner ER, Endtz HP, De Klerk MA, Tio-Gillen AP, van den Braak N, Jacobs BC, van Doorn, PA. Structure of Campylobacter jejuni lipopolysaccharides determines antiganglioside specificity and clinical features of Guillain-Barré and Miller Fisher patients. Infect Immun 2002; 70(3): 1202-8.

  27. Ang CW, De Klerk MA, Endtz HP, Jacobs BC, Laman JD, van der Meché FG, van Doorn PA. Guillain-Barré syndrome and Miller Fisher syndrome-associated Campylobacter jejuni lipopolysaccharides induce anti-GM1 and anti-GQ1b antibodies in rabbits. Infect Immun 2001; 69(4): 2462–9.

  28. Goodyear CS, O’Hanlon GM, Plomp JJ, Wagner ER, Morrison I, Veitch J, Cochrane L, Bullens RW, Molenaar PC, Conner J, Willison HJ. Monoclonal antibodies raised against Guillain-Barré syndrome-associated Campylobacter jejuni lipopolysaccharides react with neuronal gangliosides and paralyze muscle-nerve preparations. J Clin Invest 1999; 104(6): 697-708.

  29. Yuki N, Yamada M, Koga M, Odaka M, Susuki K, Tagawa Y, Ueda S, Kasama T, Ohnishi A, Hayashi S, Takahashi H, Kamijo M, Hirata K. Animal model of axonal Guillain-Barré syndrome induced by sensitization with GM1 ganglioside. Ann Neurol 2001; 49(6): 712-20.

  30. Tauxe RV. Epidemiology of Campylobacter jejuni infections in the United States and other industrialized nations. Nachamkin I, Blaser MJ, Tompkins LS (Eds.). Campylobacter jejuni: Current Status and Future Trends. Washington, DC: American Society for Microbiology; 1992, p. 9-19.

  31. Hughes RAC, Rees JH. Clinical and epidemiologic features of Guillain-Barré syndrome. J Infect Dis 1997; 176(Suppl 2): S92-S98.

  32. Winer JB, Hughes RA, Anderson MJ, Jones DM, Kangro H, Watkins RP. A prospective study of acute idiopathic neuropathy II. Antecedent events. J Neurol Neurosurg Psychiatry 1988; 51(5): 613-18.

  33. Koga M, Yuki N, Takahashi M, Saito K, Hirata K. Close association of IgA anti-ganglioside antibodies with antecedent Campylobacter jejuni infection in Guillain–Barré and Fisher’s syndromes. J Neuroimmunol 1998; 81(1-2): 138-43.

  34. Patton CM, Wachsmuth IK, Evins GM, Kiehlbauch JA, Plikaytis BD, Troup N, Tompkins L, Lior H. Evaluation of 10 methods to distinguish epidemic-associated Campylobacter strains. J Clin Microbiol 1991; 29(4): 680-8.

  35. Kuroki S, Saida T, Nukina M, Haruta T, Yoshioka M, Kobayashi Y, Nakanishi H. Campylobacter jejuni strains from patients with Guillain-Barré syndrome belong mostly to Penner serogroup 19 and contain beta-N-acetylglucosamine residues. Ann Neurol 1993; 33(3): 243-7.

  36. Goddard EA, Lastovica AJ, Argent AC. Campylobacter 0:41 isolation in Guillain-Barré syndrome. Arch Dis Child 1997; 76(6): 526-8.

  37. Lastovica AJ, Goddard EA, Argent AC. Guillain-Barré syndrome in South Africa associated with Campylobacter jejuni O:41 strains. J Infect Dis 1997; 176(Suppl 2): S139-S143.

  38. Yurochko AD, Huang ES. Immunological methods for the detection of human cytomegalovirus. J Sinclair (Ed.). Methods in molecular medicine, Vol. 33: Cytomegalovirus Protocols. Humana Press Inc; 2000, p. 1.

  39. Boucquey D, Sindic CJ, Lamy M, Delmee M, Tomasi JP, Laterre EC. Clinical and serological studies in a series of 45 patients with Guillain-Barré syndrome. J Neurol Sci 1991; 104(1): 56-63.

  40. Visser LH, van der Meché FG, Meulstee J, Rothbarth PP, Jacobs BC, Schmitz PI, van Doorn PA. Cytomegalovirus infection and Guillain-Barré syndrome: the clinical, electrophysiologic, and prognostic features. Dutch Guillain-Barré Study Group. Neurology 1996; 47(3): 668-73.

  41. Khalili-Shirazi A, Gregson N, Gray I, Rees J, Winer J, Hughes R. Antiganglioside antibodies in Guillain-Barré syndrome after a recent cytomegalovirus infection. J Neurol Neurosurg Psychiatry 1999; 66(3): 376-9.

  42. Irie S, Saito T, Nakamura K, Kanazawa N, Ogino M, Nukasawa T, Ito H, Tamai Y, Kowa H. Association of anti-GM2 antibodies in Guillain-Barré syndrome with acute cytomegalovirus infection. J Neuroimmunol 1996; 68(1-2): 19-26.

  43. Jacobs BC, van Doorn PA, Groeneveld JH, Tio-Gillen AP, van der Meché FG. Cytomegalovirus infections and anti-GM2 antibodies in Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry 1997; 62(6): 641-3.

  44. Yuki N, Tagawa Y. Acute cytomegalovirus infection and IgM anti–GM2 antibody. J Neurol Sci 1998; 154(1): 14-17.

  45. Adelmann M, Linington C. Molecular mimicry and the autoimmune response to the peripheral nerve myelin PO glycoprotein. Neurochem Res 1992; 17(9): 887-91.

  46. Khalili-Shirazi A, Hughes RA, Brostoff SW, Linington C, Gregson N. T cell response to myelin proteins in Guillain-Barré syndrome. J Neurol Sci 1992; 111(2): 200-3.

  47. Linington C, Lassmann H, Ozawa K, Kosin S, Mongan L. Cell adhesion molecules of the immunoglobulin supergene family as tissue-specific autoantigens: induction of experimental allergic neuritis (EAN) by P0 protein-specific T cell lines. Eur J Immunol 1992; 22(7): 1813-17.

  48. Dowling PC, Cook SD. Role of infection in Guillain-Barré syndrome: laboratory confirmation of herpesviruses in 41 cases. Ann Neurol 1981; 9(Suppl): S44-S55.

  49. Hadden RD, Karch H, Hartung HP, Zielasek J, Weissbrich B, Schubert J, Weishaupt A, Cornblath DR, Swan AV, Hughes RA, Toyka KV. Preceding infections, immune factors, and outcome in Guillain–Barré syndrome. Neurology 2001; 56(6): 758-65.

  50. Lacaille F, Zylberberg H, Hagege H, Roualdes B, Meyrignac C, Chousterman M, Girot R. Hepatitis C associated with Guillain-Barré syndrome. Liver 1998; 18(1): 49-51.

  51. Roccatagliata L, Uccelli A, Murialdo A. Guillain-Barré syndrome after reactivation of varicella-zoster virus. N Engl J Med 2001; 344(1): 65-6.

  52. Sanders EA, Peters AC, Gratana JW, Hughes RA. Guillain-Barré syndrome after varicella-zoster infection. Report of two cases. J Neurol 1987; 234(6): 437-9.

  53. Howlett WP, Vedeler CA, Nyland H, Aarli JA. Guillain-Barré syndrome in northern Tanzania: a comparison of epidemiological and clinical findings with western Norway. Acta Neurol Scand 1996; 93(1): 44-9.

  54. Mori M, Kuwabara S, Miyake M, Noda M, Kuroki H, Kanno H, Ogawara K, Hattori T. Haemophilus influenzae infection and Guillain-Barré syndrome. Brain 2000; 123(10): 2171-8.

  55. Hemachudha T, Griffin DE, Chen WW, Johnson RT. Immunologic studies of rabies vaccination-induced Guillain-Barré syndrome. Neurology 1988; 38(3): 375-8.

  56. Geier MR, Geier DA, Zahalsky AC. Influenza vaccination and Guillain-Barré syndrome small star, filled. Clin Immunol 2003; 107(2): 116-21.

  57. Adams D, Gibson JD, Thomas PK, Batchelor JR, Hughes RA, Kennedy L, Festenstein H, Sachs J. HLA antigens in Guillain-Barre syndrome. Lancet 1977; 2(8036): 504-5.

  58. Latovitzki N, Suciu-Foca N, Penn AS, Olarte MR, Chutorian AM. HLA typing and Guillain-Barré syndrome. Neurology 1979; 29(5): 743-5.

  59. Rees JH, Vaughan RW, Kondeatis E, Hughes, RA. HLA-class II alleles in Guillain-Barré syndrome and Miller-Fisher syndrome and their association with preceding Campylobacter jejuni infection. J Neuroimmunol 1995; 62(1): 53-7.

  60. Parkhill J, Wren BW, Mungall K, Ketley JM, Churcher C, Basham D, Chillingworth T, Davies, RM, Feltwell T, Holroyd S, Jagels K, Karlyshev AV, Moule S, Pallen MJ, Penn CW, Quall MA, Rajandream MA, Rutherford KM, van Vliet AH, Whitehead S, Barrell BG. The genome sequence of the food-borne pathogen Campylobacter jejuni reveals hypervariable sequences. Nature 2000; 403(6770): 665-8.



>Revistas >Revista Mexicana de Neurociencia >Año2005, No. 5
 

· Indice de Publicaciones 
· ligas de Interes 






       
Derechos Resevados 2019